Shares in drug reference content software vendor Epocrates Inc. rose more than 20 percent soon after trading started for its initial public offering of stock on Feb. 2.

The San Mateo, Calif.-based company raised its price before trading started from $13-15 to $16 per share. That raised the potential value of the IPO to $98.6 million. Epocrates' technology enables clinicians to access drug information via mobile computing devices at the point of care.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access